Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

Microbes and Infection

Volumn 9, Issue 4, 2007, Pages 529-535

  Rijal, Suman ^a   Yardley, Vanessa ^b   Chappuis, François ^c   Decuypere, Saskia ^d   Khanal, Basudha ^a   Singh, Rupa ^a   Boelaert, Marleen ^d   De Doncker, Simonne ^b   Croft, Simon ^b   Dujardin, Jean Claude ^b  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Drug resistance; Kala azar; Leishmania donovani; Nepal; Pentavalent and trivalent antimonials

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIMONY; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDIA; LEISHMANIA DONOVANI; NEPAL; NONHUMAN; PARASITE ISOLATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PROGNOSIS; TREATMENT OUTCOME;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 33947373049     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.01.009     Document Type: Article

References (26)

1. World Health Organization. The Leishmaniasis and Leishmania/HIV Coinfections. Fact sheet No. 116 (2000), WHO, Geneva
2. World Health Organization, Control of the Leishmaniases. Report of a WHO Expert Committee, Geneva. World Health Organization Technical Reports 793 (1990) 1-158.
3. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., Kumar P.C., and Murray H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31 (2000) 1104-1107
4. ICMR, Minutes of the Expert Group Meeting on Drug Therapy in Leishmaniasis, New Delhi, 2000.
5. Rijal S., Chappuis F., Singh R., Bovier P.A., Acharya P., Karki B.M., Das M.L., Desjeux P., Loutan L., and Koirala S. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 350-354
6. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19 (2006) 111-126
7. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6 (2001) 849-854
8. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., and Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180 (1999) 564-567
9. Abdo M.G., Elamin W.M., Khalil E.A., and Mukhtar M.M. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation, East Mediterr. Health J. 9 (2003) 837-843
10. EDCD. The Annual Internal Assessment of Malaria and Kala-azar Control Activities. Epidemiology and Disease Control Division (2002), Ministry of Health, Kathmandu, Nepal
11. Tintaya K.W., Ying X., Dedet J.P., Rijal S., De Bolle X., and Dujardin J.C. Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. J. Infect. Dis. 189 (2004) 1035-1043
12. Yardley V., Ortuño N., Llanos-Cuentas A., Chappuis F., De Doncker S., Ramirez L., Croft S., Arevalo J., Adaui V., Bermudez H., Decuypere S., and Dujardin J.C. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility?. J. Infect. Dis. 194 (2006) 1168-1175
13. Das V.N., Ranjan A., Bimal S., Siddique N.A., Pandey K., Kumar N., Verma N., Singh V.P., Sinha P.K., and Bhattacharya S.K. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl. Med. J. India 18 (2005) 131-133
14. Yardley V., Croft S.L., De Doncker S., Dujardin J.C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., and Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73 (2005) 272-275
15. Carter K.C., Sundar S., Spickett C., Pereira O.C., and Mullen A.B. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. 47 (2003) 1529-1535
16. Dube A., Singh N., Sundar S., and Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 96 (2005) 216-223
17. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., and Saravia N. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 193 (2006) 1375-1383
18. Shaked-Mishan P., Ulrich N., Ephros M., and Zilberstein D. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 276 (2001) 3971-3976
19. Wyllie S., Cunningham M.L., and Fairlamb A.H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 279 (2004) 39925-39932
20. Mookerjee B.J., Mookerjee A., Sen P., Bhaumik S., Banerjee S., Naskar K., Choudhuri S.K., Saha B., Raha S., and Roy S. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob. Agents Chemother. 50 (2006) 1788-1797
21. Rais S., Perianin A., Lenoir M., Sadak A., Rivollet D., Paul M., and Deniau M. Sodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human blood. Antimicrob. Agents Chemother. 44 (2000) 2406-2410
22. Dasgupta B., Roychoudhury K., Ganguly S., Kumar Sinha P., Vimal S., Das P., and Roy S. Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann. Trop. Med. Parasitol. 97 (2003) 245-257
23. Kocyigit A., Gur S., Gurel M.S., Bulut V., and Ulukanligil M. Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasi. Infect. Immun. 70 (2002) 6589-6591
24. Murray H.W., Oca M.J., Granger A.M., and Schreiber R.D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 83 (1989) 1253-1257
25. Murray H.W., and Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68 (2000) 288-293
26. Murray H.W., Montelibano C., Peterson R., and Sypek J.P. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182 (2000) 1497-1502